APPENDICES. A systematic review and economic model of the ...

Study Intervention Participants Outcomes
Core symptoms
CPRS: hyperactivity index
ACTeRs: attention and hyperactivity
Abbreviated Conners’ Rating Scale (ACRS)
(teachers)
Teacher ratings: attention and impulsivity
Inclusion criteria
1. CTRS or CPRS score of at least 15
Arm 1
MPH plus attention control
0.3 mg/kg/dose administered twice
daily; mean dosage 20.08 mg/day
(10–40 mg/day); 22 1-hour sessions
[Administered by trainer (attention
control)]
Reference
Brown et al., 1986 42
Source
AHRQ Report
Setting
USA
Co-existent problems
ACTeRS: oppositional and social skills
Humphrey scale: self-control
Diagnostic criteria
DSM-III
Number
Total randomised = 40 (male = 28/33)
Arm 1 = 7
Arm 2 = 10
Arm 3 = 9
Arm 4 = 7
Arm 2
Placebo plus cognitive therapy
22 1-hour sessions twice weekly on
an individual basis
[Administered by trainer (cognitive
therapy)]
Design
Parallel trial
Educational performance
WRAT: Reading, Arithmetic and Spelling
Durell Analysis of Reading Difficulty: listening
comprehension
Total withdrawals = 7
40 children began the study. Baseline characteristics and results
are given only for the 33 who completed the study and for
whom follow-up indicators are available
Duration
Treatment programme:
3 months; follow-up:
3 months after
termination of
treatment programme
Psychological function
Weschler Intelligence Scale for Children –
Revised: Freedom from Distractibility Factor
(WISC-R, FFD)
Matching Familiar Figures Test (MFFT)
Children’s Checking Test (CCT)
Detroit Tests of Learning Ability: three
attention subtests 49,71,296
Age
9 years 1 month (mean); 5 years 8 months–13 years 1 month
(range); 1 year 10 months (SD)
Arm 3
MPH plus cognitive therapy
0.3 mg/kg/dose administered twice
daily; mean dosage 20.08 mg/day
(10–40 mg/day); 22 1-hour sessions
twice weekly on an individual basis
[Administered by trainer (cognitive
therapy)]
Purpose
To investigate the
efficacy of
methylphenidate and an
adjunctive cognitive
behavioural
management
programme
© Queen’s Printer and Controller of HMSO 2006. All rights reserved.
IQ
96.73 (mean)
Health Technology Assessment 2006; Vol. 10: No. 23
Depression or anxiety
Not reported
Co-morbid disorders
Conduct disorder: 16%
Quality of life
Not reported
Diagnostic subtypes
ADD: 8 children; ADD-H: 25 children
Arm 4
Placebo plus attention control
22 1-hour sessions
[Administered by trainer (attention
control)]
Adverse events
Not reported
Additional information
No relevant information reported
Additional outcomes
Not reported
221